PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.

Michael WangJ B LawrenceD V QuonJ DucoreM L SimpsonL N BoggioIan S MitchellG YuanW A AlexanderJ-F Schved

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)

The dose-dependent efficacy seen in this study supports individualizing the initial dose of eptacog beta to optimize clinical response. By reducing uncertainty, the PERSEPT 1 results should increase the adoption of early haemostasis as a treatment goal for clinicians who treat haemorrhage in the inhibitor population.

Keyphrases

replacement therapy
drug induced